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Pathophysiology associated with several psychiatric disorders has been linked to
inflammatory biomarkers. This has generated a theory of major depressive disorders
as an inflammatory disease. The idea of pro-inflammatory cytokines altering behavior is
now well accepted however many questions remain. Microglia can produce a plethora
of inflammatory cytokines and these cells appear to be critical in the link between
inflammatory changes and depressive disorders. Microglia play a known role in sickness
behavior which has many components of depressive-like behavior such as social
withdrawal, sleep alterations, and anorexia. Numerous candidate genes have been
identified for psychiatric disorders in the last decade. Single nucleotide polymorphisms
(SNPs) in the human P2X7 gene have been linked to bipolar disorder, depression,
and to the severity of depressive symptoms. P2X7 is a ligand-gated cation channel
expressed on microglia with lower levels found on astrocytes and on some neuronal
populations. In microglia P2X7 is a major regulator of pro-inflammatory cytokines of
the interleukin-1 family. Genetic deletion of P2X7 in mice is protective for depressive
behavior in addition to inflammatory responses. P2X7−/− mice have been shown to
demonstrate anti-depressive-like behavior in forced swim and tail suspension behavioral
tests and stressor-induced behavioral responses were blunted. Both neurochemical
(norepinephrine, serotonin, and dopamine) and inflammatory changes have been
observed in the brains of P2X7−/− mice. This review will discuss the recent evidence
for involvement of P2X7 in the pathophysiology of depressive disorders and propose
mechanisms by which altered signaling through this ion channel may affect the
inflammatory state of the brain.
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Inflammation as a Theory for Pathogenesis of Mood-Related
Behavioral Changes
Recent evidence suggests that activation of inflammatory responses may contribute to the
pathogenesis of affective disorders such as depression, bipolar disorders and schizophrenia.
Results from studies of clinical psychosis indicate high levels of pro-inflammatory macrophage-
derived cytokines in both serum and plasma in psychotic relative to normal patients. Much
of the available research to date has focused on circulating levels of pro-inflammatory agents,
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including the key interleukins (particularly IL-6, IL-2, IL-1β),
tumor necrosis factor (TNF-α) and its receptors, and interferon
gamma (IFN-γ) in schizophrenia (Gaughran, 2002; Drzyzga
et al., 2006), bipolar disorder (O’Brien et al., 2006; Hope
et al., 2009) and depression (Hiles et al., 2012; Liu et al.,
2012; Dahl et al., 2014). However there is also increasing
evidence of inflammatory cytokines and activation of microglia
in the brains of affective disorder subjects. In schizophrenic
patients elevated levels of IL-6 (Garver et al., 2003; Sasayama
et al., 2013) and IL-1β cytokines (Miller et al., 2011) have
been observed in cerebrospinal fluid (CSF); while in bipolar
disorder an increase in IL-1β in the CSF of patients was recently
found (Söderlund et al., 2011). Cytokines, in turn, promote
detrimental neuronal consequences through activation of neuro-
inflammatory cascades involving microglial release of oxidative
species. Several post-mortem studies have reported an increased
density of microglia in the hippocampus (Bayer et al., 1999)
and regions of the prefrontal, cingulate and temporal cortices
(Bayer et al., 1999; Radewicz et al., 2000; Steiner et al., 2008).
Indeed, imaging and histological studies also report increased
levels astrocyte and microglial markers (e.g., glial fibrillary acidic
protein, GFAP, CD11b) in the prefrontal cortex (Rao et al., 2010)
and hippocampus (Haarman et al., 2014) in bipolar patients
and increased microglial priming and macrophage recruitment
in the cingulate cortex of depressed brains (Torres-Platas et al.,
2014). Moreover, in CSF collected from depressive patients,
increases in inflammatory mediators, such as kynurenine and
quinolinic acid released from microglia, are correlated with
increased IFN-α, soluble TNF-α receptor 2 and the chemokine
monocyte chemo-attractant protein (MCP-1) in CSF (Raison
et al., 2010). While there should also be consideration of
the external influence of medications (lithium, antidepressants
antipsychotics), age, and patient health status (such as metabolic
syndrome or chronic pain) which can all have their own
inflammatory influences, it is still clear that elevated immune-
inflammatory signaling activity is important in the etiology
of mood disorders.
Sickness Behavior; Inflammation-Related
Behavioral Changes
The origin of pro-inflammatory cytokines found in the
brain is yet to be clearly elucidated. While cytokines can
be produced centrally, it is also of consideration that they
are released by circulating immune cells and move to the
brain through specific transport mechanisms such as via the
circumventricular organs or across a dysfunctioning blood
brain barrier. Evidence from animal studies indeed show
that activation of the peripheral immune system influences
brain pathology, cytokine levels, and behavior. Exposure to
the bacterial endotoxin lipopolysaccharide (LPS) or the viral
immunostimulant polyinosinic: polycytidylic acid (poly I:C)
can induce sickness behavior, a depressive-like state where
reductions in food consumption, body weight, social interaction
and activity are observed (Yirmiya, 1996; Cunningham et al.,
2007). This so-called sickness behavior is both a physical and
psychological illness and is observed in humans, encompassing
such complications as fatigue, lethargy, anhedonia, anorexia,
and muscle and joint pain (Dantzer, 2009). Triggered by the
production of pro-inflammatory cytokines by the immune
system, it is thought to be part of a highly organized strategy to
fight infections.
There are several glial (non-neuronal) cell populations in
the brain, notably astrocytes, microglia and oligodendrocytes.
The activation of brain microglia has been associated with
depressive-like behavior in a number of recent studies (Tynan
et al., 2010; Hinwood et al., 2012; Kreisel et al., 2014). In many
cases psychological stress induced through prolonged restraint
or unpredictable events, is demonstrated to alter microglial
responses upregulating various cellular activation markers such
as Iba-1, CD11b, and MHC Class II. The number and density
of microglia in particular brain regions appears to be altered
on the same time-scale as the behavioral changes. Dynamic
changes in both number and activation status of microglia have
been recently documented with acute increases in microglial
number followed by a decline in number with more sustained
(chronic) stress (Kreisel et al., 2014). Potentially, this early
increased density of activated microglia could amplify pro-
inflammatory signaling through the release of inflammatory
and neurotoxic mediators such as cytokines. Blocking the
initial activation with minocycline rescued the decline in
microglial numbers and the behavioral change (Kreisel et al.,
2014).
P2X7 is an Ion Channel Regulating
Inflammatory Signaling
P2X7 is a purinergic ion channel activated by the known
danger signal molecule and neurotransmitter, ATP (Bartlett
et al., 2014). Many immune cells express this purinergic ion
channel including myeloid lineage cells such as macrophages
and their brain-resident counterparts, microglia. P2X7
expression is not restricted to microglia in the brain, with
astrocytes, oligodendrocytes and certain populations of
neurons exhibiting low levels of expression (reviewed in
Bartlett et al., 2014). Over the last decade research into
understanding the role of this ion channel in immune cell
responses has revealed a critical function in the regulation
of cytokine secretion from macrophages and microglia. It
is clear that activation of P2X7 is a major physiological
stimulus for rapid secretion of IL-1 family cytokines from
macrophages and microglia (Ferrari et al., 1997, 2006).
Evidence for involvement of P2X7 activation in regulating
other pro-inflammatory cytokine secretion is less robust
although there is evidence for a role in IL-6 secretion from
macrophages (Solle et al., 2001) and both TNF-α and IL-6
secretion from microglia (Shieh et al., 2014). In addition to
cytokines P2X7 is involved in inflammatory prostaglandin
secretion (Barberà-Cremades et al., 2012) and release of
lysosomal proteases such as cathepsins (Lopez-Castejon et al.,
2010).
Transgenic mice deficient in P2X7 (P2X7−/−) were generated
over a decade ago and have aided our understanding of the
physiological and pathophysiological roles of this ion channel.
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P2X7−/− mice were originally demonstrated to display reduced
cytokine responses (Solle et al., 2001) and subsequent studies
have documented reduced inflammatory-related disorders such
as anti-collagen induced arthritis (Labasi et al., 2002). Ex
vivo macrophages isolated from P2X7−/− mice display no
secretion of IL-1β, IL-18 and IL-1α cytokines in response to in
vitro priming and challenge with ATP (Pelegrin et al., 2008).
Furthermore, intraperitoneal injection of LPS into P2X7−/−
mice caused a reduced febrile response compared to wild-
type mice, which was restored upon injection of recombinant
IL-1β (Barberà-Cremades et al., 2012). This suggests that
P2X7−induced IL-1β secretion plays a key pyrogenic role
in vivo. The behavioral effects of injected LPS were not
investigated by Barberà-Cremades et al. (2012), however a
separate study by Csölle et al. (2013b) has demonstrated that
LPS-induced anhedonia measured using a sucrose preference
test is reduced in P2X7−/− mice. These studies suggest
that inflammatory responses to LPS are reduced in P2X7
deficient mice.
P2X7 and Microglial Responses
Early studies demonstrated that activation of P2X7 stimulated
IL-1β cytokine release from mouse microglial cells (Ferrari
et al., 1997). Experiments utilizing P2X7−/− mice demonstrated
that P2X7 was crucial for ATP-mediated IL-1β release from
microglia and that P2X7 deficiency attenuated LPS-induced
expression of both IL-1β and TNFα (Mingam et al., 2008).
In addition to control of cytokines, P2X7 on microglial cells
has been linked to glial cytotoxicity, with the induction of
apoptotic cell death following prolonged stimulation (Bartlett
et al., 2013). P2X7 on microglia can also induce cortical
neuron cell injury in a co-culture model system, using a
process not requiring direct cellular contact (Skaper et al.,
2006). Microglia deficient in P2X7 or treated with a P2X7
antagonist did not induce neuronal toxicity in this study
highlighting a key role for this ion channel in secreting
mediators capable of reducing neuronal viability (Skaper et al.,
2006).
More recently P2X7 has been implicated in cellular
proliferative responses in microglia amongst other cell types,
with a study reporting that overexpression of P2X7 was sufficient
to drive proliferation and activation of microglia (Monif
et al., 2009). These observations are complemented by a study
investigating basal and TNFα cytokine-induced proliferation in
hippocampal-entorhinal slices where P2X7 was demonstrated
to play a key role in proliferation (Zou et al., 2012). The
involvement of P2X7 in microglial responses is summarized in
Figure 1.
P2X7 Deficient Mice are Resilient to
Depressive-like Behavior
Four studies by different groups have so far investigated
the effect of genetic deletion of P2X7 on behavior using
standard depression tests in mice, namely the forced swim
test and tail suspension test. All four studies demonstrated
FIGURE 1 | P2X7 on central glial cells may drive inflammation. Resting
microglia express purinergic receptors including P2X7. Induction of microglial
activation and proliferation increases microglial density in the brain. P2X7 is
involved in both activation and proliferation of microglia. The presence of ATP,
the major agonist for P2X7 channels would drive release of pro-inflammatory
mediators from central microlia. These could amplify activation and
proliferation of glia and induce toxic damage to neurons and neuronal
signaling pathways potentially driving behavioral changes.
a significant reduction in immobility time in P2X7−/− mice,
a feature associated with anti-depressive behavior (Basso
et al., 2009; Boucher et al., 2011; Csölle et al., 2013a,b).
Differences between genotypes were more obvious after repeated
challenge or stress suggesting that the demonstrated resilience
is more pronounced to stressor-induced behavioral changes.
Pharmacological blockade of P2X7 was also effective in altering
depressive-like behavior and LPS-induced sickness behavior in
mice (Csölle et al., 2013a,b). Selective, centrally penetrating
P2X7 modulators may have potential for further development as
therapies for CNS disorders including affective disorders. Three
P2X7 antagonists A-438079, JNJ-47965567, and JNJ-42253432,
have recently been demonstrated to attenuate amphetamine-
induced behavioral sensitization in rodents (Bhattacharya et al.,
2013; Gubert et al., 2014; Lord et al., 2014), a key process
underlying motivational behavior. Moreover antidepressant and
anxiolytic like behavior is observed after P2X7 antagonism in
animal models exhibiting depressive-like symptomatology in
forced swim and social interaction paradigms (Pereira et al.,
2013; Lord et al., 2014; Wilkinson et al., 2014).
A major finding from the work by Csölle et al. (2013a)
was that peripheral immune cells such as infiltrating monocytes
or macrophages do not appear to be involved in protection
from depressive behavior associated with P2X7 deficiency. To
demonstrate this they used bone marrow chimera experiments.
Here mice were irradiated to destroy circulating immune cells
and underwent a bone marrow transplant from donor mice
which were either wild-type (P2X7+) or knockout (P2X7−).
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Reconstituted mice with both P2X7 expressing and P2X7
deficient bonemarrow demonstrated no difference in immobility
time in the tail suspension test. The study concluded that
deficiency of P2X7 only in peripheral immune cells gave no
protection from depressive-like behavior (Csölle et al., 2013a).
Whilst this study also suggested central microglia were not
involved through the same bone marrow chimera approach,
more data would be helpful to strengthen this particular
conclusion. For example, does central injection of IL-1β restore
depressive-like behavior in the P2X7−/− mouse? This would
indicate whether cytokines were driving depressive behavior.
In addition, these behavioral studies use C57BL/6 mice which
are known to carry a single nucleotide polymorphism (SNP)
in the C-terminus of P2X7 affecting downstream signaling
pathways including cytokine secretion (Adriouch et al., 2002).
It would be interesting and relevant to determine if this effect
is maintained in mouse strains carrying a high functioning
P2X7.
Significant differences in expression (both up- and down-
regulation) of genes involved in synaptic signaling were found
by whole genome microarrays in the amygdala of P2X7−/−
mice (Csölle et al., 2013a). Moreover, exposure to restraint
stress caused an acute elevation in adrenocorticotropic hormone
(ACTH) and corticosterone levels in wild-type C57BL/6 mice
but this was reduced in P2X7−/− mice (Csölle et al., 2013a).
This suggests that P2X7 deficiency may blunt the stress hormone
response. The anterior pituitary, which is responsible for the
production of stress hormones amongst others, expresses P2X
channels (Koshimizu et al., 2000; Zemkova et al., 2006) and ATP
is known to modulate ACTH secretion. Therefore it is possible
P2X7 may play a role in the amplification of secretagogue signals
from the hypothalamus.
A Mutant P2X7 Allele Linked to Depression
and Bipolar Disorder in Human Studies
There have been a number of genetic studies over the last decade
linking a SNP in the human P2RX7 gene to depression, anxiety,
and bipolar disorder (Barden et al., 2006; Lucae et al., 2006;
McQuillin et al., 2009; Soronen et al., 2011). Inheritance of the
minor allele of this SNP (rs2230912-G) has also been correlated
to severity of depression in diabetic and psychiatric patients
(Hejjas et al., 2009; Nagy et al., 2008; Halmai et al., 2013). In
contrast there are several genetic studies that do not find an
association with P2RX7 genotype at this polymorphic site and
bipolar disorder, major depression or schizophrenia (Green et al.,
2009; Viikki et al., 2011). A recent meta-analysis also suggested
no association (Feng et al., 2014). Addressing the functional
relevance of this SNP in vitro studies on circulating immune
cells isolated from humans carrying the rs2230912-G allele have
demonstrated that this genetic variant of P2X7 is inherited
on a gain-of-function allele (Stokes et al., 2010). Importantly
human monocytes expressing this rs2230912-G variant secreted
more IL-1β in response to activation of P2X7 than monocytes
expressing a wild-type variant (Stokes et al., 2010). Therefore
one could speculate that microglia in the brain may also
display enhanced cytokine secretion in response to P2X7 ion
channel activation. Whilst this is difficult to demonstrate in
the human system, a transgenic mouse approach knocking-
in this human variant of P2X7 could begin to address this
question.
In transgenic mouse studies genetic deletion of P2X7
eliminates a full-length P2X7 protein and protects against
depressive learned helplessness behavior (Basso et al., 2009;
Boucher et al., 2011; Csölle et al., 2013a). Could this also be
true for humans? There are numerous loss-of-function SNPs in
the human P2X7 gene which are demonstrated to have dramatic
effects on receptor trafficking or receptor function (Sluyter and
Stokes, 2011). Several studies have included some (but not all)
loss-of-function P2X7 SNPs in their analysis but no difference in
genotype frequency has so far been documented (Barden et al.,
2006; Hansen et al., 2008).
The Gliotransmitter ATP and Depressive
Behavior
The purinergic signaling system is extensive in the body
involving many receptors, ion channels and enzymes. ATP
is a known co-transmitter released at synapses and extra-
synaptic sites modulating the responses of glial and neurons
(Burnstock, 2008). A recent study by Cao et al. presents a
novel case for astrocyte-derived ATP as a rapid anti-depressant
neurotransmitter (Cao et al., 2013). But how does this idea
fit with a role for P2X7 (and potentially other purinergic
receptors) in depressive disorders? Cao et al. (2013) suggest
that astrocytes release ATP in the medial prefrontal cortex
where the P2X2 receptor seems to be the downstream target
for this anti-depressant action of ATP as evidenced by shRNA
experiments. Astrocytes and microglia both express P2X7, which
can be activated by relatively high concentrations of ATP
(>100 µM); levels that may not be achieved in the brain
where nucleotidases are widely expressed (Robson et al., 2006).
Thus astrocyte-derived ATP may not reach concentrations high
enough to stimulate pro-inflammatory signaling through P2X7.
In P2X7−/− mice, which demonstrate an antidepressant-like
phenotype, Csölle et al. (2013a) demonstrated an up-regulation
of a number of genes in the amygdala including P2RX2 (11-
fold change). Together with the evidence that immune cells
(including microglia) do not affect the behavioral phenotype,
perhaps this highlights a role for astrocytes, ATP, and P2X2, in
the antidepressant effect of P2X7 deficiency? It is clear that more
studies are required to understand the role of purinergic signaling
in psychiatric disorders.
Future Perspectives
In humans a correlation between high functioning P2X7 and
affective disorders is often observed but this may be limited
to patients with an inflammatory component, for example
diabetic patients. Perhaps understanding more about the clinical
features associated with affective disorders will lead to a useful
stratification of these disorders and co-morbidity with other
diseases. The evidence for involvement of P2X7 in depressive
disorders from animal studies is promising but it is clear
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that more information about this ion channel and its role in
inflammation and behavior is needed. Microglia are known to
play a role in stress-induced depressive behavior but is P2X7
a major driver of inflammatory signaling in central microglia
under conditions of chronic stress? P2X7 is not restricted
to microglia and it is likely that astrocytes participate in
regulation of microglial and neuronal responses. Future studies
will hopefully address these issues and begin to determine
whether this ion channel could be a novel drug target for affective
disorders.
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